Equities

LivaNova PLC

LivaNova PLC

Actions
  • Price (USD)81.59
  • Today's Change0.06 / 0.07%
  • Shares traded298.96k
  • 1 Year change+50.79%
  • Beta0.8846
Data delayed at least 15 minutes, as of Oct 21 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

LivaNova PLC is a medical device company. The Company is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The Company operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

  • Revenue in USD (TTM)1.02bn
  • Net income in USD-379.12m
  • Incorporated2015
  • Employees4.00k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Integer Holdings Corp1.11bn96.72m3.03bn7.50k31.532.3117.112.742.922.9233.3939.840.45365.015.30147,652.103.962.294.242.4727.4929.448.735.191.753.730.33720.00-14.686.05-15.30--2.89--
Axonics Inc150.27m-68.17m3.10bn416.00--6.14--20.62-1.68-1.683.7510.940.32871.147.56361,221.20-14.91---15.87--61.94---45.36--10.73-7.310.0002--707.06--31.30------
Patterson Companies, Inc.6.28bn165.57m3.11bn7.80k18.773.1812.730.49521.701.7064.5610.072.336.8716.84805,269.906.10-0.34759.84-0.49219.5421.732.62-0.19960.7877--0.3914--7.691.88126.51-3.43-20.132.93
Cytek Biosciences Inc-100.00bn-100.00bn3.20bn429.00--------------1.37------------------------6.76--0.00--60.39--119.11------
AtriCure Inc.243.13m-56.68m3.32bn750.00--8.62--13.65-1.29-1.295.538.390.3461.758.57324,177.30-8.07-8.44-8.72-9.3574.6072.67-23.31-17.002.94-11.740.1251---10.529.74-36.83---17.12--
Adapthealth Corp1.75bn-90.37m3.38bn8.70k--1.78101.661.93-1.97-1.9718.8214.530.643526.248.29200,718.00-4.61---5.47--20.40---7.16--0.84071.190.5004--102.15---657.38------
Haemonetics Corporation903.41m64.49m3.66bn2.71k56.965.4023.884.051.261.2617.6913.270.55991.566.59333,609.304.003.924.984.9146.2746.027.145.591.576.200.53670.00-11.94-0.8593.85---18.40--
Merit Medical Systems, Inc.1.03bn28.24m3.98bn5.99k141.404.0133.853.860.50060.500618.3117.650.61412.807.06172,185.201.681.361.901.5243.5643.602.742.171.2112.000.22760.00-3.1112.20-280.57---1.41--
Nevro Corp409.13m-68.27m4.19bn843.00--11.70--10.25-1.97-1.9711.8310.280.60491.386.71485,327.40-10.09-12.91-12.90-15.3270.0069.17-16.69-17.966.37-1.600.2901---7.2339.0719.89--3.77--
Conmed Corp978.50m54.14m4.23bn3.40k83.805.6833.524.321.731.7331.7925.530.56142.266.26287,794.403.111.603.451.7955.2954.665.532.751.172.400.49596.80-9.703.70-66.75-20.78-2.810.00
LivaNova PLC1.02bn-379.12m4.34bn4.00k--3.84--4.25-7.79-7.8020.9721.240.41712.335.55255,431.00-15.47-4.59-19.29-5.5365.3064.85-37.09-11.050.9711-0.67770.3892---13.83---120.85------
Inari Medical Inc208.18m25.02m4.44bn456.00198.3019.97162.7121.330.44840.44843.734.450.87121.388.88456,526.3010.47--11.49--92.15--12.02--6.65298.980.00--173.17--1,256.96------
Premier Inc1.72bn260.84m4.87bn2.60k16.682.1811.452.832.382.3814.6418.200.53197.154.53661,981.609.4115.8011.5819.5448.6564.2017.7031.720.845315.070.17675.9932.448.16-56.39-20.442.91--
ICU Medical Inc1.28bn103.26m4.89bn7.90k48.353.1425.623.824.774.7759.0473.430.69842.608.03161,866.005.645.286.626.0736.7637.998.076.283.671,172.470.00190.000.378830.05-14.0214.0748.43--
Pacific Biosciences of California Inc105.83m-77.21m5.09bn412.00--19.70--48.10-0.4648-0.46480.53891.300.1453.496.77256,856.80-10.58-37.11-12.03-46.5342.7139.54-72.96-74.8625.78-22.210.7762---13.20-3.19134.95---19.16--
Helen of Troy Limited2.16bn214.61m5.50bn1.77k26.314.3321.872.548.668.6687.5052.600.9462.545.211,223,043.009.389.5512.3611.7343.8642.299.9210.480.808222.990.2714--22.928.5558.7921.3442.70--
Data as of Oct 21 2021. Currency figures normalised to LivaNova PLC's reporting currency: US Dollar USD

Institutional shareholders

44.29%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20215.11m9.61%
PRIMECAP Management Co.as of 30 Jun 20214.02m7.56%
Harris Associates LPas of 30 Jun 20213.79m7.12%
Barrow, Hanley, Mewhinney & Strauss LLCas of 30 Jun 20212.22m4.17%
SSgA Funds Management, Inc.as of 30 Jun 20211.97m3.71%
Eminence Capital LPas of 30 Jun 20211.65m3.11%
Hawk Ridge Capital Management LPas of 30 Jun 20211.30m2.44%
Paradice Investment Management LLCas of 30 Jun 20211.19m2.23%
Bestinver Gesti�n SA SGIICas of 30 Jun 20211.16m2.19%
Maverick Capital Ltd.as of 30 Jun 20211.15m2.16%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.